View Item 
      •   R2KN Home
      • Kementerian Kesehatan
      • Badan Penelitian dan Pengembangan Kesehatan
      • Jurnal Balitbangkes
      • Jurnal Penelitian dan Pengembangan Pelayanan Kesehatan
      • (eJournal 1) Jurnal Penelitian dan Pengembangan Pelayanan Kesehatan
      • View Item
      •   R2KN Home
      • Kementerian Kesehatan
      • Badan Penelitian dan Pengembangan Kesehatan
      • Jurnal Balitbangkes
      • Jurnal Penelitian dan Pengembangan Pelayanan Kesehatan
      • (eJournal 1) Jurnal Penelitian dan Pengembangan Pelayanan Kesehatan
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Should Off-Label Medicines Be Included in the Universal Health Coverage (UHC) Schemes? Why, When, and How?

      Date
      2017
      Author
      Mulyani, Ully Adhie; HTA Program Mahidol University, Research Center Building, Faculty of Medicine Ramathibodi Hospital, Mahidol University 270 RAMA VI Road. Rachathevi, Bangkok 10400, Thailand.
      Metadata
      Show full item record
      Abstract
      Off label medicine refers to any medicine that is used to treat any ailment beyond of its approved / licensed indication by National Regulatory Authorities, such us FDA in USA and BPOM in Indonesia. Off-label medicines are used because the available and approved drugs do not have the desired effect, then doctors try medicine that have not been licensed indications. Some other reasons in practice off-label medicines use and prescribing are that drugs in the same category have the same effect (although have not been approved by indication); the expansion to a lighter form than the licensed indication, or extension of use for certain related conditions. At the opposite, the disadvantage of the practice off-label medicine use is generally not included in any health insurance benefit package, also not covered by mandatory insurance scheme (JKN-BPJS). Patients should pay for the price of a drug that has not been assured or proven of its efficacy and safety. It needs strong evidence based on scientific research to ensure the safety and effectiveness of off-label medicines to be included in the list of medications (national formulary) to put it on National Health Insurance (BPJS) benefit package.
      URI
      http://ejournal.litbang.kemkes.go.id/index.php/jpppk/article/view/8044
      Collections
      • (eJournal 1) Jurnal Penelitian dan Pengembangan Pelayanan Kesehatan [16]

      Copyright © Badan Litbangkes - Kementerian Kesehatan RI
      Jl. Percetakan Negara no.29, Jakarta Pusat 10560, Indonesia
      All rights reserved. 2019
      Contact Us | Send Feedback
        

       

      Browse

      All of R2KNCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

      My Account

      LoginRegister

      Copyright © Badan Litbangkes - Kementerian Kesehatan RI
      Jl. Percetakan Negara no.29, Jakarta Pusat 10560, Indonesia
      All rights reserved. 2019
      Contact Us | Send Feedback